Continue to Order Nirsevimab (Beyfortus™). Respiratory syncytial virus (RSV) activity still in California.

Dear VFC Provider,

RSV season is here, with more than 10.1% of respiratory specimens in California testing positive for RSV during the week ending December 16, 2023. It is critical to continue protecting your most vulnerable patients from RSV disease.
If your practice sees young or vulnerable infants and have not yet ordered nirsevimab (Beyfortus™), order now to protect as many patients as possible with available VFC supplies, following CDC’s Interim CDC Recommendations to Protect Infants from Respiratory Syncytial Virus (RSV) during the 2023–2024 Respiratory Virus Season.

Ordering Tips:
All VFC providers may order 50mg and 100 mg doses of nirsevimab (Beyfortus™) in limited quantities. Doses approved will be based on ordering history of index routine infant vaccines (hepatitis B vaccine birth doses for hospitals, first doses of pneumococcal conjugate vaccine for all other providers).

Providers who have previously requested and received nirsevimab may request additional doses. Nirsevimab re-orders will be approved based on usage and on-hand inventory of nirsevimab, as well as available supply.

Current limits and eligibility are subject to change based on supply.

Once immunizations are received, please make sure doses administered are reported to CAIR, following the appropriate VFC Eligibility. VFC doses must only be administered to VFC-eligible patients. Borrowing is not allowed.

The following resources can help your practice ensure prioritization of high-risk populations in light of limited nirsevimab supply: IMM-1480 Nirsevimab (Beyfortus) Guide to Prevent Severe RSV in Infants and Toddlers (eziz.org).

Thank you,
California Department of Public Health | Immunization Branch
Vaccines for Children (VFC) Program
850 Marina Bay Parkway
Richmond, CA 94804
Phone: 877-2GET-VFC (877-243-8832)
Fax: 877-FAXX-VFC (877-329-9832)
Email: MyVFCVaccines@cdph.ca.gov